Denali Therapeutics Inc. (NASDAQ:DNLI) Expected to Announce Quarterly Sales of $26.63 Million

Wall Street analysts expect that Denali Therapeutics Inc. (NASDAQ:DNLI) will report sales of $26.63 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Denali Therapeutics’ earnings. The highest sales estimate is $70.00 million and the lowest is $4.00 million. Denali Therapeutics posted sales of $9.39 million during the same quarter last year, which would indicate a positive year over year growth rate of 183.6%. The firm is expected to issue its next earnings results on Thursday, November 4th.

On average, analysts expect that Denali Therapeutics will report full year sales of $100.49 million for the current fiscal year, with estimates ranging from $38.86 million to $170.90 million. For the next fiscal year, analysts expect that the business will report sales of $92.30 million, with estimates ranging from $38.86 million to $150.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Denali Therapeutics.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Wednesday, August 4th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). The company had revenue of $22.94 million for the quarter, compared to analysts’ expectations of $27.92 million. Denali Therapeutics had a net margin of 15.66% and a return on equity of 5.31%. Denali Therapeutics’s revenue was up 292.3% compared to the same quarter last year.

A number of equities research analysts recently commented on DNLI shares. HC Wainwright reiterated a “buy” rating and issued a $105.00 target price (up previously from $95.00) on shares of Denali Therapeutics in a research report on Monday, July 26th. Sumitomo Mitsui Financial Group began coverage on shares of Denali Therapeutics in a research note on Wednesday, September 1st. They issued an “outperform” rating and a $78.00 price objective on the stock. UBS Group assumed coverage on shares of Denali Therapeutics in a research report on Tuesday, May 18th. They set a “buy” rating and a $70.00 target price for the company. Zacks Investment Research raised Denali Therapeutics from a “sell” rating to a “hold” rating and set a $54.00 price target on the stock in a research report on Wednesday, August 18th. Finally, Morgan Stanley decreased their price objective on Denali Therapeutics from $100.00 to $99.00 and set an “overweight” rating for the company in a report on Monday, August 16th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $78.56.

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction on Wednesday, June 23rd. The stock was sold at an average price of $70.74, for a total value of $117,852.84. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Carole Ho sold 6,143 shares of the stock in a transaction dated Monday, August 23rd. The shares were sold at an average price of $48.91, for a total transaction of $300,454.13. The disclosure for this sale can be found here. Insiders have sold a total of 77,558 shares of company stock worth $4,118,686 in the last quarter. Insiders own 17.00% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Arizona State Retirement System increased its holdings in shares of Denali Therapeutics by 1.2% in the first quarter. Arizona State Retirement System now owns 22,690 shares of the company’s stock valued at $1,296,000 after purchasing an additional 270 shares during the last quarter. Ensign Peak Advisors Inc increased its stake in shares of Denali Therapeutics by 0.7% in the 2nd quarter. Ensign Peak Advisors Inc now owns 41,942 shares of the company’s stock worth $3,290,000 after acquiring an additional 300 shares during the last quarter. Meeder Asset Management Inc. increased its stake in shares of Denali Therapeutics by 12.5% in the 2nd quarter. Meeder Asset Management Inc. now owns 2,747 shares of the company’s stock worth $215,000 after acquiring an additional 306 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in shares of Denali Therapeutics during the 2nd quarter worth $29,000. Finally, ClariVest Asset Management LLC boosted its position in shares of Denali Therapeutics by 2.8% during the 1st quarter. ClariVest Asset Management LLC now owns 17,206 shares of the company’s stock valued at $982,000 after acquiring an additional 473 shares during the last quarter. Institutional investors and hedge funds own 65.66% of the company’s stock.

Denali Therapeutics stock traded up $1.93 during trading hours on Friday, hitting $53.76. 17,287 shares of the stock traded hands, compared to its average volume of 572,369. The firm’s 50 day moving average price is $56.70 and its 200-day moving average price is $60.08. The stock has a market capitalization of $6.54 billion, a price-to-earnings ratio of 189.31 and a beta of 1.88. Denali Therapeutics has a 1 year low of $33.68 and a 1 year high of $93.94.

About Denali Therapeutics

Denali Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

See Also: What is the accumulation/distribution indicator?

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.